Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia

European Psychiatry

Volumn 29, Issue 1, 2014, Pages 1-10

  Schneider, C ^a   Corrigall, R ^a   Hayes, D ^a   Kyriakopoulos, M ^a   Frangou, S ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Clozapine; Early onset; Efficacy; Paediatric; Schizophrenia; Tolerability

Indexed keywords

CLOZAPINE;

ABNORMAL BLOOD PRESSURE; AGRANULOCYTOSIS; AKATHISIA; BODY WEIGHT DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CARDIOVASCULAR EFFECT; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CONSCIOUSNESS DISORDER; CONSTIPATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ENDOCRINE DISEASE; ENURESIS; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERSALIVATION; METABOLIC DISORDER; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SEIZURE; SHORT SURVEY; SYSTEMATIC REVIEW; TACHYCARDIA; UROGENITAL TRACT DISEASE; WEIGHT GAIN;

CLOZAPINE; EARLY ONSET; EFFICACY; PAEDIATRIC; SCHIZOPHRENIA; TOLERABILITY;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; EARLY DIAGNOSIS; HUMANS; SCHIZOPHRENIA;

EID: 84892535501     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2013.08.001     Document Type: Short Survey

References (47)

1. Alfaro C.L., Wudarsky M., Nicolson R., Gochman P., Sporn A., Lenane M., et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 2002, 12:83-91.
2. American Academy of Child Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001, 40(7 Suppl.):4-23.
3. Armenteros J.L., Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry 2006, 15:141-148.
4. Cannon M., Jones P., Huttunen M.O., Tanskanen A., Huttunen T., Rabe-Hesketh S., et al. School performance in Finnish children and later development of schizophrenia: a population-based longitudinal study. Arch Gen Psychiatry 1999, 5:457-463.
5. Cannon T.D., Rosso I.M., Bearden C.E., Sanchez L.E., Hadley T. A prospective cohort study of neurodevelopmental processes in the genesis and epigenesis of schizophrenia. Dev Psychopathol 1999, 11:467-485.
6. Cirulli G. Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units. Psychiatr Bull 2005, 29:377-380.
7. Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother 2012, 13:1545-1573.
8. Couchman L., Bowskill S.V., Handley S., Patel M.X., Flanagan R.J. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18years: data from a therapeutic drug monitoring service, 1994-2010. Early Interv Psychiatry 2013, 7:122-130.
9. De Hert M., Dobbelaere M., Sheridan E.M., Cohen D., Correll C.U. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011, 26:144-158.
10. De Hert M., Hudyana H., Dockx L., Bernagie C., Sweers K., Tack J., et al. Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry 2011, 26:34-44.
11. Eggers C., Bunk D. The long-term course of childhood-onset schizophrenia: a 42-year follow-up. Schizophr Bull 1997, 23:105-117.
12. Fitton A., Heel R.C. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990, 40:722-747.
13. Fleischhaker C., Heiser P., Hennighausen K., Herpertz-Dahlmann B., Holtkamp K., Mehler-Wex C., et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol 2006, 16:308-316.
14. Fleischhaker C., Heiser P., Hennighausen K., Herpertz-Dahlmann B., Holtkamp K., Mehler-Wex C., et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 2008, 115:1599-1608.
15. Fraguas D., Merchán-Naranjo J., Laita P., Parellada M., Moreno D., Ruiz-Sancho A., et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008, 69:1166-1175.
16. Frazier J.A., Gordon C.T., McKenna K., Lenane M.C., Jih D., Rapoport J.L. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994, 33:658-663.
17. Freedman J.E., Wirshing W.C., Russel A.T., Palmer Bray M., Jergen U. Absence status seizures after successful long-term clozapine treatment of an adolescent with schizophrenia. J Child Adolesc Psychopharmacol 1994, 4:53-62.
18. Gerbino-Rosen G., Roofeh D., Tompkins D.A., Feryo D., Nusser L., Kranzler H., et al. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 2005, 44:1024-1031.
19. Gochman P., Miller R., Rapoport J.L. Childhood-onset schizophrenia: the challenge of diagnosis. Curr Psychiatry Rep 2011, 13:321-322.
20. Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007, 30:47-57.
21. Hafner H., Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Nerurosci 1995, 245:80-92.
22. Hrdlicka M., Zedkova I., Blatny M., Urbanek T. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. Neuro Endocrinol Lett 2009, 30:256-261.
23. Hummer M., Kurz M., Barnas C., Saria A., Fleischhacker W.W. Clozapine-induced transient white blood count disorders. J Clin Psychiatry 1994, 55:429-432.
24. Kim Y., Kim B.N., Cho S.C., Kim J.W., Shin M.S. Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: a retrospective study in Korean children and adolescents. Hum Psychopharmacol 2008, 23:715-722.
25. Koller E., Malozowski S., Doraiswamy P.M. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001, 286:2547-2548.
26. Kumra S., Frazier J.A., Jacobsen L.K., McKenna K., Gordon C.T., Lenane M.C., et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996, 53:1090-1097.
27. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., DeThomas C., Cullen K., et al. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol 2008, 18:307-316.
28. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006, 163:1273-1276.
29. Lay B., Blanz B., Hartmann M., Schmidt M.H. The psychosocial outcome of adolescent onset schizophrenia: a 12-year follow-up. Schizophr Bull 2000, 26:801-816.
30. Maziade M., Bouchard S., Gingras N., Charron L., Cardinal A., Roy M.-A., et al. Long-term stability of diagnosis and symptom dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence. II: positive/negative distinction and childhood predictors of adult outcome. Br J Psychiatry 1996, 169:371-378.
31. Merrill D.B., Dec G.W., Goff D.C. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005, 25:32-41.
32. Mukhopadhaya K., Krishnaiah R., Taye T., Nigam A., Bailey A.J., Sivakumaran T., et al. Obsessive-compulsive disorder in UK clozapine- treated schizophrenia and schizoaffective disorder: a cause for clinical concern. J Psychopharmacol 2009, 23:6-13.
33. Munro J., O'Sullivan D., Andrews C., Arana A., Mortimer A., Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999, 175:576-580.
34. National Institute for Health and Clinical Excellence. Psychosis and schizophrenia in children and young people, recognition and management, 2013. http://www.nice.org.uk/nicemedia/live/12951/60475/60475.pdf.
35. Newcome J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
36. Palmer S.E., McLean R.M., Ellis P.M., Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. Clin Psychiatry 2008, 69:759-768.
37. Peyrière H., Roux C., Ferard C., Deleau N., Kreft-Jais C., Hillaire-Buys D., et al. Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiol Drug Saf 2009, 18:948-955.
38. Praharaj S.K., Arora M., Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl) 2006, 185:265-273.
39. Röpcke B., Eggers C. Early-onset schizophrenia: a 15-year follow-up. Eur Child Adolesc Psychiatry 2005, 14:341-350.
40. Schulz E., Fleischhaker C., Remschmidt H.E. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. J Child Adolesc Psychopharmacol 1996, 6:119-131.
41. Shaw P., Sporn A., Gogtay N., Overman G., Greenstein D., Gochman P., et al. Childhood-onset schizophrenia. A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006, 63:721-730.
42. Sikich L., Frazier J.A., McClellan J., Findling R.L., Vitiello B., Ritz L., et al. Double-blind comparison of first and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008, 165:1420-1431.
43. Sporn A.L., Vermani A., Greenstein D.K., Bobb A.J., Spencer E.P., Clasen L.S., et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007, 46:1349-1356.
44. Turetz M., Mozes T., Toren P., Chernauzan N., Yoran-Hegesh R., Mester R., et al. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 1997, 170:507-510.
45. Vyas N.S., Hadjulis M., Vourdas A., Byrne P., Frangou S. The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up. Eur Child Adolesc Psychiatry 2007, 16:465-470.
46. Wehmeier P.M., Schuler-Springorum M., Heiser P., Remschmidt H. Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine. J Child Adolesc Psychopharmacol 2004, 14:267-271.
47. Wudarsky M., Nicolson R., Hamburger S.D., Spechler L., Gochman P., Bedwell J., et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999, 9:239-245.